Background: Asthma and chronic obstructive pulmonary disease (COPD) are prevalent obstructive lung diseases with distinct inflammatory pathways but overlapping clinical features. Bronchodilator responsiveness (BDR) is a key diagnostic criterion, yet its metabolic determinants are poorly understood. Objective: This cross-sectional study investigated whether integrated profiling of exhaled volatile organic compounds (VOCs) and clinical biomarkers can differentiate BA, COPD, and health, and predict BDR. Methods: Exhaled breath from 160 BA patients, 128 COPD patients, and 254 healthy controls was analyzed in real-time using proton-transfer reaction time-of-flight mass spectrometry (PTR-TOF-MS) during tidal and forced expiration. Clinical assessment included spirometry, fractional exhaled nitric oxide (FeNO), blood eosinophil count, and total IgE. Machine-learning (XGBoost) was employed for feature selection and model development. Results: Distinct VOC signatures effectively discriminated disease groups from controls and from each other. The model for distinguishing asthma from healthy controls achieved an AUC of 0.747 during normal quiet breathing and 0.710 during forced exhale. For discriminating COPD from healthy controls, the model performance was higher, with an AUC of 0.821 for normal quiet breathing and 0.856 for forced exhale. A model integrating VOC profiles with clinical biomarkers (FeNO, eosinophils, IgE) demonstrated very high accuracy in internal validation in predicting BDR (AUC = 1.000 for tidal breathing; AUC = 0.970 for forced expiration). Specific mass spectral features (m/z 79, m/z 101) were significantly associated with a positive BDR test. Conclusions: This study delineates disease-specific VOC signatures and underscores the profound synergy between exhaled metabolomics and clinical immunology for identifying associations treatment response, advocating for the integration of real-time breath analysis into personalized management strategies for obstructive lung diseases.
Lymphangioleiomyomatosis (LAM) is a rare progressive disease that affects women of reproductive age and is characterized by cystic lung destruction, airflow obstruction, and lymphatic dysfunction. Current diagnostic methods are costly or lack sufficient specificity, highlighting the need for novel non-invasive approaches. Exhaled breath analysis using real-time proton mass spectrometry (PTR-MS) presents a promising strategy for identifying disease-specific volatile organic compounds (VOCs). This cross-sectional study analyzed exhaled breath samples from 51 LAM patients and 51 age- and sex-matched healthy controls. PTR-time-of-flight mass spectrometry (PTR-TOF-MS) was employed to identify VOC signatures associated with LAM. Data preprocessing, feature selection, and statistical analyses were performed using machine learning models, including gradient boosting classifiers (XGBoost), to identify predictive biomarkers of LAM and its complications. We identified several VOCs as potential biomarkers of LAM, including m/z = 90.06 (lactic acid) and m/z = 113.13. VOCs predictive of disease complications included m/z = 49.00 (methanethiol), m/z = 48.04 (O-methylhydroxylamine), and m/z = 129.07, which correlated with pneumothorax, obstructive ventilation disorders, and radiological findings of lung cysts and bronchial narrowing. The classifier incorporating these biomarkers demonstrated high diagnostic accuracy (AUC = 0.922). This study provides the first evidence that exhaled breath VOC profiling can serve as a non-invasive additional tool for diagnosing LAM and predicting its complications. These findings warrant further validation in larger cohorts to refine biomarker specificity and explore their clinical applications in disease monitoring and personalized treatment strategies.
31 July 2024 in Russian Journal of Occupational Health and Industrial Ecology
Hypersensitive pneumonitis (HP) is an inflammatory interstitial lung disease (ILD) that occurs in predisposed individuals in response to repeated exposure to various aerosol antigens. In 2020 and 2021, specialists made changes to the latest clinical recommendations, to the classification of HP, allowing to distinguish between fibrous and non-fibrous types of HP. The fibrous type is associated with the progression of the disease and an unfavorable prognosis. The diagnosis of HP and its division into types are based on a combination of clinical and anamnestic data, a high-resolution computed tomography (HRCT) picture, the results of cytological examination of bronchoalveolar lavage (BAL) and lung biopsy. Specialists also use lung function tests to determine the progression of the disease. The key diagnostic method is high-resolution computed tomography, which reveals signs of lung tissue pathology ("frosted glass", mosaic density) and signs of damage to the small respiratory tract (centrilobular foci, air traps). In fibrotic HP, experts have identified signs of fibrosis: traction bronchiectasis, reticular changes, decreased lung volume, and the formation of a "cellular lung" is possible. Non-fibrotic HP is characterized by: lymphocytic cytogram type (more than 30% of the total number of cells), while in fibrotic HP lymphocytosis is less common. Experts often use lung biopsies for differential diagnosis with other diseases. In nonfibrotic HP, scientists evaluate the signs of involvement of bronchioles and adjacent alveoli in the inflammatory process, the nature of inflammatory infiltration and the presence of granulomas. Fibrotic HP has bronchiolocentric fibrosis, chronic interstitial pneumonia, peribronchiolar metaplasia and other signs. HP therapy includes the elimination of contact with the antigen, the administration of glucocorticosteroids and/or immunosuppressants, as well as antifibrotic therapy in the presence of a progressive variant of fibrous HP.
Challenges in the differential diagnosis of SARS-CoV-2-induced viral pneumonia and interstitial lung diseases (ILD), especially those that were previously undiagnosed, newly-onset or acute, have been identified based on data from the COVID-19 pandemic. Viral infections are known to be a risk factor for the development and exacerbation of ILD. In COVID-19, acute lung injury occurs with the development of inflammatory changes in the pulmonary interstitium, which may lead to the fibrotic formation of the lung tissue. Currently, the problem of ILD and COVID-19 remains extremely urgent, given the difficulties in differential diagnosis of the acute phase of COVID-19, post-COVID-19 changes, and various nosological forms of ILD, and the significant impact of COVID-19 on the course of an underlying ILD. The aim of this review was to highlight the features of the differential diagnosis of ILD and viral pneumonia caused by SARS-CoV-2, and to investigate the impact of COVID-19 on the course of ILD. Conclusion. The differential diagnosis of ILD and COVID-19 viral pneumonia should consider a combination of features of the disease onset, clinical findings, changes on high-resolution computed tomography (HRCT), laboratory data, and identification of SARS-CoV-2.